Drug Discovery

BenevolentAI becomes first AI company to appoint a Chief Medical Officer

11 January 2017 | By Niamh Marriott (Drug Target Review)

BenevolentAI is the first AI company to have a CMO on its staff.

Chronos and Aptuit partner up for addictive behaviour programmes

11 January 2017 | By Niamh Marriott (Drug Target Review)

The companies will work together on integrated drug discovery - medicinal and computational chemistry, biology and DMPK - to optimise Chronos’ selective orexin 1 antagonists that have shown promise in treating addiction.

Mission Therapeutics appoints Colin Goddard as Chairman

21 December 2016 | By Niamh Marriott (Drug Target Review)

Mission Therapeutics have appointed Dr Colin Goddard as non-executive Chairman, effective January 1st 2017.

Molecular Devices

Valid biomarker signatures from liquid biopsies – how to standardise NGS

6 December 2016 | By Benedikt Kirchner (TUM School of Life Sciences and Ludwig-Maximilians-University Munich), Dominik Buschmann (TUM School of Life Sciences and Ludwig-Maximilians-University Munich), Michael W. Pfaffl (TUM School of Life Sciences)

The advent of next-generation sequencing (NGS) techniques has revolutionised transcriptomics research and opened numerous avenues for scientific and clinical applications. While reverse transcriptase quantitative real-time polymerase chain reaction (RT-qPCR) is still considered the gold standard of gene expression analysis, its high throughput, single-nucleotide resolution and ever-plummeting costs have made NGS…

Versatile applications of next-generation sequencing in pharmaceutics

4 December 2016 | By Pushpanathan Muthuirulan (National Institutes of Health)

Next-generation sequencing (NGS) technologies hold great promise for unravelling the mysteries of biological systems, with the advent of DNA sequencing methods having greatly accelerated biomedical research, gaining broad applicability in disease diagnosis and therapeutics in recent years...

DiscoverX In Vitro Pharmacology Services – Simplify Your Drug Discovery Workflow

21 October 2016 | By DiscoverX Corporation

Monitoring cellular drug penetration and drug-target interaction enables assessment of compound efficacy and confirmation of mode of action...

Charles River Laboratories acquires Agilux Laboratories, Inc.

13 October 2016 | By Charles River Laboratories

Enhances Charles River’s early-stage capabilities in bioanalytical services...

Whitepaper: Uncover specific correlations in heterogeneous cell populations during drug development

3 October 2016 | By Bio-Rad Laboratories

Integrating the S3e™ Cell Sorter into sample preparation upstream of the QX200™ Droplet Digital System provided details about cell subpopulations that would have been undetectable in heterogeneous populations...

Charles River Laboratories and The Tri-Insitutional Therapeutics Discovery Institute announce strategic partnership

26 September 2016 | By Charles River Laboratories

Partnership intends to accelerate translation of discoveries into novel therapies for patients...

Whitepaper: Accelerating Gαq GPCR Drug Discovery with recognized and reliable tool

26 September 2016 | By Cisbio Bioassays

Cisbio Bioassays has developed a GPCR platform based on the company’s HTRF® technology to measure second messenger accumulation...

A picture is worth a thousand endpoints: high-content imaging in drug discovery

12 September 2016 | By Debra Taylor (MRC Technology), Emilie Bureau (MRC Technology), Janet Brownlees (MRC Technology)

Over the past few years several factors in the drug discovery industry have come together to drive an increased interest and subsequent surge in the use of high-content imaging. These include the high costs of attrition in the clinic due to lack of efficacy; increased hurdles and rising costs to…

Hit-to-lead in drug discovery

4 September 2016 | By Douglas B. Kitchen (Albany Molecular Research Inc.), Mark Wolf (Albany Molecular Research Inc.)

Starting in the 1970s, the drug discovery research process changed dramatically. Our understanding of biological targets and pathways grew and the largely empirical and target agnostic in vivo pharmacology approach was replaced with target-centric methods...

App note: HTRF technology essentials to boost your research

23 August 2016 | By Cisbio Bioassays

In this application note, learn how to reduce time and sample consumption while achieving highly reproducible results from your assays with HTRF technology...

Charles River Laboratories announces partnership with the Milner Therapeutics Institute and Consortium

10 August 2016 | By Charles River Laboratories

Charles River Laboratories announced that it has entered into a strategic partnership with the Milner Therapeutics Institute and Consortium...